BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CureDuchenne and PPMD Announce Webinar on FDA, Medical Product Regulation, and Advocate Involvement


6/17/2010 10:03:08 AM

CORONA DEL MAR, Calif.--(BUSINESS WIRE)--How does the FDA make its decisions? Who makes the rules for drug development? What special accommodations are made for rare diseases? Cure Duchenne and Parent Project Muscular Dystrophy are happy to bring you this two-part live Webinar series featuring Dr. David Banks of the FDA Office of Special Health Issues. Dr. Banks will walk us through the general steps required for approving a drug with special emphasis on the implications of the Orphan Drug Act, individual INDS and expanded access programs. This series is meant to be interactive—participants can either type in questions that will be displayed during the discussion or submit questions in advance. These talks will attempt to provide some insights into the FDA’s mission--what are its constraints, and what are its goals? Dr. Banks will not be able to address questions about specific therapeutics that are undergoing regulatory review right now, but can talk about general principles and how they might be applied. The topics in the two series will be different.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES